Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
Kuldeep Singh Bhadauria, Senior Brand Lead of Hematology, Rare Disease and Immunology at Takeda, shared a post on LinkedIn:
“Hemophilia Care Transition…..
Haemophilia care in India is undergoing a profound transition due to significant focus of Innovation hubs shifts to Rare Diseases Like Roche, Novo Nordisk, Sanofi , Pfizer.
The Convergence of low-dose prophylaxis (LDP), non-factor therapies such as Emicizumab and Concizumab, Extended half-life products and the emergence of gene therapy is reshaping the treatment paradigm and creating Unprecedented Possibilities for improving patient outcomes.
The market is therefore transitioning from a predominantly on-demand, factor-replacement model toward proactive, prophylaxis-led and increasingly factor-independent care.
However, India’s progress remains uneven. While pockets of excellence exist across leading haemophilia centres, significant gaps still persist in diagnosis, prophylaxis penetration, affordability, access, laboratory capability and continuity of care.
The Next Phase of haemophilia care in India……
will be defined not only by innovation, but by our ability to make innovation accessible and scalable.
Key opportunity pools
Haemophilia A
The largest opportunity pool, driven by the high prevalence of FVIII deficiency and rapid adoption of non-factor therapies.
Haemophilia B
A smaller patient population but a strategically attractive segment because of the limited non-factor treatment options historically available, creating potential for rebalancing therapies.
Inhibitors
A high-unmet-need segment with an estimated market of approximately ₹450 Cr, providing an important beachhead for novel haemostatic approaches
Winning Strategy is Creating a Ecosystem not just scaling brand alone..
The winning strategy will combine clinical differentiation, affordability, patient identification, government access, HFI engagement, laboratory readiness and real-world evidence.
Pateint Centricity, Hemophilia Federation India (HFI) is a critical stakeholder in the Indian haemophilia ecosystem.
Strong P3 (Public-Private-Patient group) collaboration will be Beach Head and winning equation to build sustainable and scalable ecosystem to expand Reach of Innovative care to million Hemophilics and improve QOL .
This equation will strengthen Healthy India objective.
Lets work together……”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 11:04Wolfgang Miesbach: The Critical Need for Tailored Dosing in VWD
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda